Title: ARL9 is Upregulated and Serves as a Biomarker for a Poor Prognosis in Colon
Adenocarcinoma
Version: 1 Date: 07 Dec 2022
Reviewer:  Mansoor-ali Vaali-mohammed
Reviewer's report:
Dear Author
Manuscript describes well that  ARL9 mRNA is upregulated and serves as a Biomarker in Colon
adenocarcinoma.
The following steps should provide more clear information in the manuscript.
1) Please provide Clinicopathological data of ARL9 in 437 colon adenocarcinoma samples.
2) In the materials section – please clearly mention catalog number, company name and
restructured the materials and methods section including western blotting.
3) Figure 7 – mentioned in Tubulin control antibody but in the manuscript GAPDH?. Please
provide densitometry analysis.
4) ARL9 knockdown experiments – only HCT116 CRC cell lines are used, minimum TWO
CRC cell lines are required to understand well.
5) Please carefully check through the manuscript regarding grammatical errors etc.
Title: ARL9 is Upregulated and Serves as a Biomarker for a Poor Prognosis in Colon
Adenocarcinoma
Version: 1 Date: 07 Dec 2022
Reviewer:  Mansoor-ali Vaali-mohammed
Reviewer's report:
Dear Author
Manuscript describes well that  ARL9 mRNA is upregulated and serves as a Biomarker in Colon
adenocarcinoma.
The following steps should provide more clear information in the manuscript.
1) Please provide Clinicopathological data of ARL9 in 437 colon adenocarcinoma samples.
2) In the materials section – please clearly mention catalog number, company name and
restructured the materials and methods section including western blotting.
3) Figure 7 – mentioned in Tubulin control antibody but in the manuscript GAPDH?. Please
provide densitometry analysis.
4) ARL9 knockdown experiments – only HCT116 CRC cell lines are used, minimum TWO
CRC cell lines are required to understand well.
5) Please carefully check through the manuscript regarding grammatical errors etc.
Please review this paper.
user
Title: ARL9 is Upregulated and Serves as a Biomarker for a Poor Prognosis in Colon
Adenocarcinoma
Version: 1 Date: 07 Dec 2022
Reviewer:  Mansoor-ali Vaali-mohammed
Reviewer's report:
Dear Author
Manuscript describes well that  ARL9 mRNA is upregulated and serves as a Biomarker in Colon
adenocarcinoma.
The following steps should provide more clear information in the manuscript.
1) Please provide Clinicopathological data of ARL9 in 437 colon adenocarcinoma samples.
2) In the materials section – please clearly mention catalog number, company name and
restructured the materials and methods section including western blotting.
3) Figure 7 – mentioned in Tubulin control antibody but in the manuscript GAPDH?. Please
provide densitometry analysis.
4) ARL9 knockdown experiments – only HCT116 CRC cell lines are used, minimum TWO
CRC cell lines are required to understand well.
5) Please carefully check through the manuscript regarding grammatical errors etc.
assistant